• Waldenström Macroglobulinemia
  • Melanoma
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Childhood Cancers
  • Gastric Cancer
  • Gynecologic Cancer
  • Head & Neck Cancer
  • Immunotherapy
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma Cancer
  • Mesothelioma
  • MPN
  • MDS
  • Myeloma
  • Prostate Cancer
  • Rare Cancers
  • Sarcoma
  • Skin Cancer
  • Testicular Cancer
  • Thyroid Cancer

Recognizing Metastatic Breast Cancer Awareness Day


For Metastatic Breast Cancer Awareness Day on Oct. 13, 2020, here’s a round-up of fast facts and the latest news and updates in this disease space.

For Metastatic Breast Cancer Awareness Day on Oct. 13, 2020, CURE® has collected a roundup of fast facts and the latest news and updates in this disease space:

5. The decision to forego reconstructive surgery after breast cancer is a very personal one. In this piece, a patient with metastatic disease shares her experience with self-advocacy and “going flat” after mastectomy surgery.

4. In August, the phase 3 IMpassion131 study, which set out to evaluate the immunotherapy Tecentriq (atezolizumab) in combination with the chemotherapy paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer, failed to meet its primary endpoint of improving progression-free survival, meaning that the regimen didn’t delay the time from the start of treatment until disease worsened.

metastatic breast cancer, surgery, treatment, awareness

Fast Facts on Metastatic Breast Cancer

3. After being diagnosed with stage 4 breast cancer in 2014, Marissa Holzer shares her thoughts on why patients with metastatic breast cancer need research, funding and so much more, because “six years is not enough.”

2. Nurse Stephanie Walker was thrown into a world of isolation and new depths of depression she “never knew even existed” when she was diagnosed with metastatic breast cancer. In this video blog, she details how working with a therapist and communicating with her family and friends helped her find her way out of the darkness.

1. Recent data show that the combination of pyrotinib plus Xeloda (capecitabine) provides a better progression-free survival rate than Tykerb (lapatinib) plus Xeloda in a subset of previously treated patients with HER2-positive metastatic breast cancer.

Get the latest news and updates on metastatic breast cancer from CURE® here.

Related Videos
Expert on TNBC, with patient
Addressing Unmet Needs Session Panel
Dr. Beverly Moy
Dr. Dejan Juric
HER2 and Triple-Negative Disease Session Panel
Dr. Neelima Vidula
HR-Positive Metastatic Breast Cancer Panel
Dr. Laura M. Spring
Dr. Seth A. Wander
Related Content